A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

DRUG: Placebo
DRUG: Ianalumab

Sponsor

Novartis Pharmaceuticals